Identification
NameBefunolol
Accession NumberDB09013
TypeSmall Molecule
GroupsExperimental
Description

Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

Structure
Thumb
Synonyms
(RS)-1-{7-[2-hydroxy-3-(propan-2-ylamino)propoxy]- 1-benzofuran-2-yl}ethanone
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
befunolol hydrochlorideB03Z2VY37I 39543-79-8TVVTWOGRPVJKDJ-UHFFFAOYSA-NDetails
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BenfuranNot Available
BentosKakenyaku Kakko
BetaclarNot Available
GlauconexNot Available
Brand mixturesNot Available
Categories
UNII418546MT3A
CAS number39552-01-7
WeightAverage: 291.347
Monoisotopic: 291.14705816
Chemical FormulaC16H21NO4
InChI KeyZPQPDBIHYCBNIG-UHFFFAOYSA-N
InChI
InChI=1S/C16H21NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10,13,17,19H,8-9H2,1-3H3
IUPAC Name
1-(7-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}-1-benzofuran-2-yl)ethan-1-one
SMILES
CC(C)NCC(O)COC1=CC=CC2=C1OC(=C2)C(C)=O
Pharmacology
Indication

Used in the management of open angle glaucoma. PMID: 12480285.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinunknownNot AvailableHumanP08588 details
Beta-2 adrenergic receptorProteinunknownNot AvailableHumanP07550 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Befunolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental, Illicit
AceclofenacAceclofenac may decrease the antihypertensive activities of Befunolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Befunolol.Approved
AcetohexamideBefunolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Befunolol is combined with Acetylcholine.Approved
AcetyldigitoxinBefunolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Befunolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental, Investigational
AlfentanilAlfentanil may increase the bradycardic activities of Befunolol.Approved, Illicit
AlfuzosinBefunolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Befunolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Befunolol.Approved, Investigational
AmobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Befunolol can be decreased when combined with Amodiaquine.Approved
AndrographolideHMPL-004 may decrease the antihypertensive activities of Befunolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Befunolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Befunolol.Approved
ApocyninAcetovanillone may decrease the antihypertensive activities of Befunolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
ApremilastApremilast may decrease the antihypertensive activities of Befunolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Befunolol is combined with Arecoline.Experimental
AzapropazoneAzapropazone may decrease the antihypertensive activities of Befunolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Befunolol.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Befunolol.Approved, Investigational
BarbexacloneThe serum concentration of Befunolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Befunolol can be decreased when it is combined with Barbital.Illicit
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Befunolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Illicit
Benzylpenicilloyl PolylysineBefunolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BethanecholThe risk or severity of adverse effects can be increased when Befunolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Befunolol.Investigational
BL-1020BL-1020 may increase the hypotensive activities of Befunolol.Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Befunolol.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Befunolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Befunolol.Investigational
BucindololBefunolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Befunolol.Approved, Investigational
CabergolineCabergoline may increase the hypertensive activities of Befunolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Befunolol is combined with Carbachol.Approved
CarprofenCarprofen may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved, Withdrawn
CarvedilolBefunolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Befunolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Befunolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Befunolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Befunolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
ChlorpropamideBefunolol may increase the hypoglycemic activities of Chlorpropamide.Approved
Choline magnesium trisalicylateTrisalicylate-choline may decrease the antihypertensive activities of Befunolol.Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Befunolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Befunolol.Investigational
DapoxetineThe serum concentration of Befunolol can be increased when it is combined with Dapoxetine.Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Befunolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Befunolol.Approved
DeslanosideBefunolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Befunolol.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Befunolol.Approved
DigitoxinBefunolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinBefunolol may increase the bradycardic activities of Digoxin.Approved
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Befunolol.Approved
DiltiazemDiltiazem may increase the hypotensive activities of Befunolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Befunolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Befunolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Befunolol.Approved
DoxazosinBefunolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Befunolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Befunolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
DuloxetineDuloxetine may increase the tachycardic activities of Befunolol.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Befunolol.Investigational
E-6201E6201 may decrease the antihypertensive activities of Befunolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Befunolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Befunolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Befunolol.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Befunolol is combined with EPIBATIDINE.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Befunolol.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Befunolol.Approved
ErgonovineErgonovine may increase the hypertensive activities of Befunolol.Approved
ErgotamineErgotamine may increase the hypertensive activities of Befunolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Befunolol.Approved, Investigational
EtodolacEtodolac may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Befunolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
EtoperidoneThe serum concentration of Befunolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Befunolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Befunolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Befunolol.Approved
FentanylFentanyl may increase the bradycardic activities of Befunolol.Approved, Illicit, Investigational, Vet Approved
FingolimodBefunolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Befunolol.Approved, Withdrawn
FluoxetineThe serum concentration of Befunolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Befunolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Befunolol.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Befunolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Befunolol.Approved
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Befunolol.Approved, Nutraceutical
GlibornurideBefunolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideBefunolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBefunolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBefunolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBefunolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideBefunolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideBefunolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Befunolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
HexobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Befunolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Befunolol.Investigational
HydroxychloroquineThe metabolism of Befunolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Befunolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Befunolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Befunolol.Approved
IndalpineThe serum concentration of Befunolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndomethacinIndomethacin may decrease the antihypertensive activities of Befunolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Befunolol.Withdrawn
IndoraminBefunolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBefunolol may increase the hypoglycemic activities of Insulin Pork.Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Befunolol.Approved, Withdrawn
IsoxicamIsoxicam may decrease the antihypertensive activities of Befunolol.Withdrawn
KebuzoneKebuzone may decrease the antihypertensive activities of Befunolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Befunolol.Approved
LabetalolBefunolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Befunolol.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Befunolol.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Befunolol.Approved, Vet Approved
LisofyllineLisofylline may decrease the antihypertensive activities of Befunolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Befunolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
LornoxicamLornoxicam may decrease the antihypertensive activities of Befunolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Befunolol.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Befunolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Befunolol.Approved
MalathionMalathion may increase the bradycardic activities of Befunolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Befunolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Befunolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Befunolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Befunolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Befunolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Befunolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Befunolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Befunolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Befunolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Befunolol.Investigational
MethohexitalThe serum concentration of Befunolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Befunolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Befunolol.Investigational
MethylphenobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Methylphenobarbital.Approved
MidodrineBefunolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Befunolol.Approved
MinaprineMinaprine may increase the bradycardic activities of Befunolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Befunolol.Investigational
MoricizineMoricizine may increase the hypotensive activities of Befunolol.Approved, Withdrawn
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Befunolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Befunolol.Approved
NabumetoneNabumetone may decrease the antihypertensive activities of Befunolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Befunolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Befunolol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
NefazodoneThe serum concentration of Befunolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Befunolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Befunolol.Approved
NicotineThe risk or severity of adverse effects can be increased when Befunolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Befunolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Befunolol.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Befunolol.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Befunolol.Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
OleandrinBefunolol may increase the bradycardic activities of Anvirzel.Experimental
OlopatadineOlopatadine may decrease the antihypertensive activities of Befunolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Befunolol.Approved
OuabainBefunolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Befunolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Befunolol.Withdrawn
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Befunolol.Approved
ParoxetineThe serum concentration of Befunolol can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerazinePerazine may increase the hypotensive activities of Befunolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Vet Approved, Withdrawn
PerphenazinePerphenazine may increase the hypotensive activities of Befunolol.Approved
PhenobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Befunolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Befunolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Befunolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Befunolol.Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Befunolol.Approved, Investigational
PrazosinBefunolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Befunolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Befunolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
PromazinePromazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Befunolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Befunolol.Approved
PropafenoneThe serum concentration of Befunolol can be increased when it is combined with Propafenone.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Befunolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Befunolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Befunolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Befunolol.Approved
ReserpineReserpine may increase the hypotensive activities of Befunolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Befunolol.Experimental, Investigational
RifampicinThe serum concentration of Befunolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Befunolol can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
RivastigmineRivastigmine may increase the bradycardic activities of Befunolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Befunolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved, Investigational
SalicylamideSalicylamide may decrease the antihypertensive activities of Befunolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Befunolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Befunolol.Approved
SecobarbitalThe serum concentration of Befunolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Befunolol.Approved
SertralineThe serum concentration of Befunolol can be increased when it is combined with Sertraline.Approved
SilodosinBefunolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Befunolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Befunolol.Investigational
SufentanilSufentanil may increase the bradycardic activities of Befunolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Befunolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Befunolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Befunolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Befunolol.Withdrawn
TamsulosinBefunolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Befunolol.Approved
TerazosinBefunolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Befunolol.Approved
ThiamylalThe serum concentration of Befunolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Befunolol.Withdrawn
ThiopentalThe serum concentration of Befunolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioridazineThioridazine may increase the hypotensive activities of Befunolol.Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Befunolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Befunolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
TolazamideBefunolol may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideBefunolol may increase the hypoglycemic activities of Tolbutamide.Approved
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Befunolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Befunolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Befunolol.Approved, Investigational
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Befunolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Befunolol.Approved, Vet Approved
TrimazosinBefunolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TubocurarineTubocurarine may increase the bradycardic activities of Befunolol.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Befunolol.Investigational, Withdrawn
VareniclineThe risk or severity of adverse effects can be increased when Befunolol is combined with Varenicline.Approved, Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Befunolol.Approved
VerapamilVerapamil may increase the hypotensive activities of Befunolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Befunolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Befunolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Befunolol can be increased when it is combined with Zimelidine.Withdrawn
ZomepiracZomepirac may decrease the antihypertensive activities of Befunolol.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Reichl S, Muller-Goymann CC: The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride. Int J Pharm. 2003 Jan 2;250(1):191-201. [PubMed:12480285 ]
External Links
ATC CodesS01ED06 — Befunolol
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US3853923 No1971-05-131991-05-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)115Ito, K., Mashiko, I.,Kimura, K. and Nakanishi,T.;U.S. Patent 3,853,923; December 10.1974; assigned to Kakenyaku Kakko Co., Ltd.
Predicted Properties
PropertyValueSource
Water Solubility0.108 mg/mLALOGPS
logP1.71ALOGPS
logP1.23ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)13.92ChemAxon
pKa (Strongest Basic)9.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area71.7 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity79.5 m3·mol-1ChemAxon
Polarizability32.01 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzofurans
Sub ClassNot Available
Direct ParentBenzofurans
Alternative ParentsAryl alkyl ketones / Alkyl aryl ethers / Benzenoids / Heteroaromatic compounds / Furans / Secondary alcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines / Organopnictogen compounds
SubstituentsBenzofuran / Aryl alkyl ketone / Aryl ketone / Alkyl aryl ether / Benzenoid / Furan / Heteroaromatic compound / 1,2-aminoalcohol / Ketone / Secondary alcohol
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Uniprot Name:
Beta-1 adrenergic receptor
Molecular Weight:
51322.1 Da
References
  1. Yamada Y, Takayanagi R, Tsuchiya K, Ito K, Ohtani H, Sawada Y, Iga T: Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther. 2001 Jun;17(3):235-48. [PubMed:11436944 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Uniprot Name:
Beta-2 adrenergic receptor
Molecular Weight:
46458.32 Da
References
  1. Yamada Y, Takayanagi R, Tsuchiya K, Ito K, Ohtani H, Sawada Y, Iga T: Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther. 2001 Jun;17(3):235-48. [PubMed:11436944 ]
Drug created on June 20, 2014 17:23 / Updated on August 02, 2017 17:32